Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value

Journal of Nuclear Medicine

Volumn 39, Issue 4, 1998, Pages 699-706

  Jager, Pieter L ^a   Hazenberg, Bouke P C ^a   Franssen, Eric J F ^a   Limburg, Piet C ^a   Van Rijswijk, Martin H ^a   Piers, D Albertus ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Amyloidosis; Diagnosis; Iodine 123; Serum amyloid P component

Indexed keywords

AMYLOID P COMPONENT; IODINE 123;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG CLEARANCE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOTOPE LABELING; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; AMYLOID; AMYLOIDOSIS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROGNOSIS; SERUM AMYLOID A PROTEIN; SERUM AMYLOID P-COMPONENT; SURVIVAL RATE;

EID: 0031950329     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Van der Hem GK, van Rijswijk MH. Amyloidosis, In: Cameron S, Davidson AM, Grünfeld J-P, et al., eds. Oxford textbook of clinical nephrology, 2nd ed. Oxford: Oxford University Press; 1992:545-561.
2. Husby G. Classification of amyloidosis. In: Husby G, ed. Reactive amyloidosis and the acute phase response. Baillière's clinical rheumatology. London: Baillière Tindall: 1994:503-511.
3. Hazenberg BPC, van Rijswijk MH. Clinical and therapeutic aspects of AA amyloidosis. In: Husby G, ed. Reactive amyloidosis and the acute phase response. Baillière's clinical rheumatology. London: Baillière Tindali; 1994:661-690.
4. Husby G, Marhaug G, Dowton B, Sletten K, Sipe JD. Serum amyloid A (SAA): biochemistry, genetics and the pathogenesis of AA amyloidosis. Amyloid: Int J Clin Invest 1994;1:119-137.
5. Solomon A, Weiss DT. Protein and host factors implicated in the pathogenesis of light chain amyloidosrs (AL amyfoidosis). Amyloid: Int J Clin Invest 1995;2:269-279.
6. Pepys MB, Baltz ML, de Beer FC, et al. Biology of serum amyloid P component. Ann NY Acad Sci 1982;389:286-297.
7. Pepys MB, Rademacher TW, Amatayakul-Chantler S, et al. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci USA 1994;91:5602-5606.
8. Pepys MB, Dyck RF, de Beer FC, Skinner M, Cohen AS. Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol 1979;38:284-293.
9. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentraxins) and serum amyloid A protein. Adv Immunol 1983;34:141-211.
10. Pepys MB, Dash AC, Makham RE, Thomas HC, Williams BD, Petrie A. Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol 1978;32:119-124.
11. Hutchinson WL, Noble GE, Hawkins PN, Pepys MB. The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocyes in vivo. J Clin Invest 1994;94:1390-1396.
12. Hawkins PN, Wootton R, Pepys MB. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis. J Clin Invest 1990;86:1862-1869.
13. Dyck RF, Lockwood CM, Kershaw M, et al. Amyloid P-component is a constituent of normal human glomerular basement membrane. J Exp Med 1980;152:1162-1174.
14. Breathnach SM, Melrose SM, Bhogal B, et al. Amyloid P component is located on elastic fibre microfibrils in normal human tissue. Nature 1981;293:652-653.
15. 2+-mediated association of human serum amyloid P component with heparan sulfate and dermatan sulfate. J Biol Chem 1987;262:1456-1460.
16. Perfetti V, Bellotti V, Maggi A, et al. Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease. Am J Hematol 1994;46:189-193.
17. Suhr OB, Holmgren G, Steen L, et al. Liver transplantation in familial amyloidotic polyneuropathy: follow-up of the first 20 Swedish patients. Transplantation 1995;60: 933-938.
18. Moreau P, Milpied N, de Faucal P, et al. High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement. Blood 1996;87:3063-3064.
19. Hawkins PN, Myers MJ, Lavender JP, Pepys MB. Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet 1988;i:1413-1418.
20. 123I-labeled serum amyloid P component. N Engl J Med 1990;323: 508-513.
21. Hawkins PN, Richardson S, MacSweeney JE, et al. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression. Q J Med 1993;86:365-374.
22. Hawkins PN, Richardson S, Vigushin DM, et al. Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis. Arth Rheum 1993;36:842-851.
23. Mather SJ, Ward BC. High efficiency iodination of monoclonal antibodies for radiotherapy. J Nucl Med 1987;28:1034-1036.
24. De Beer FC, Pepys MB. Isolation of human C-reactive protein and serum amyloid P component. J Immunol Methods 1982;50:17-31.
25. Hind CRK, Collins PM, Renn D, et al. Binding specificity of serum amyloid P component for the pyruvate acetyl of galactose. J Exp Med 1984;159:1058-1069.
26. Gibaldi M, Perrier D. Multicompartment models. In: Gibaldi M, Perrier D. Pharmacokinetics, first edition, New York: Dekker; 1975:45-88.
27. Baltz ML, Caspi D, Evans DJ, Rowc IF, Hind CRK, Pepys MB. Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits. Clin Exp Immunol 1986;66:691-700.
28. 131I-labelled serum amyloid P component. Arth Rheum 1987;30:1303-1306.
29. 125I-labeled amyloid P component in β2M amyloidosis: a possible approach to quantitate disease activity. Nephrol Dial Transplant 1995;10:223-229.
30. Skinner M, Vaitukaitis JL, Cohen AS, Benson MD. Serum amyloid P-component levels in amyloidosis, connective tissue diseases, infection and malignancy as compared to normal serum. J Lab Clin Med 1979;97:633-638.
31. Saïle R, Deveaux M, Hachulla E, Descamps J, Duquesnoy B, Marchandise X. Iodine-123-labeled serum amyloid P component scintigraphy in amyloidosis. Eur J Nucl Med 1993;20:130-137.
32. Koutras DA, Marketos SG, Rigopoulos GA, Malamos B. Iodine metabolism in chronic renal insufficiency. Nephron 1972;9:55-65.
33. Hachulla E, Maulin L, Deveaux M, et al. Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy: from diagnosis to prognosis. Am J Med 1996;101:77-87.
34. Kawahara E, Shiroo M, Nakanishi I, Migita S. The role of fibronectin in the development of experimental amyloidosis-evidence of immunohistochemical codistribution and binding property with serum amyloid protein-A. Am J Pathol 1989;134: 1305-1314.
35. Zahedi K. Characterization of the binding of serum amyloid P to type IV collagen. J Biol Chem 1996;271:14897-14902.